Berner Laura 4

What Happened
Laura Berner, a director of Bolt Biotherapeutics, was granted a derivative award covering 5,000 shares on June 10, 2026. The grant is reported as acquired at $0.00 per share (total reported consideration $0). This is an equity award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-10; Form filed: 2026-06-11 (filed the next day).
• Reported transaction type/code: Award/Grant (A).
• Shares subject to award: 5,000; price reported: $0.00; reported total consideration: $0.
• Shares owned after the transaction: Not specified in the provided extract.
• Footnote (F1): The award vests on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting, subject to the reporting person’s continued service; the award vests in full upon a change in control.
• Timeliness: Filing appears timely (next-day filing); no late filing flag indicated.

Context
This was a compensatory derivative grant to a director, typical of board compensation. Such awards are not open-market purchases or sales and do not represent immediate cash proceeds; vesting conditions determine when the recipient actually obtains vested shares. Because this is a grant (non-cash award), it should be viewed as executive compensation information rather than a direct bullish or bearish market action.